Treg Cell Selection for Gastrointestinal Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory bowel diseases like Crohn's disease and ulcerative colitis often involve anti-inflammatory medications with adverse reactions, and there is a lack of consistent correlation between Treg function and abundance in patient tissues, making it difficult to identify suitable Treg cells for cellular immunotherapy.
Innovation Solution
Identification of Treg cells with specific homing receptor expression patterns that can migrate to and localize in the gastrointestinal tract, particularly for Crohn's disease, using markers like CCR9, α4β7, and α4+αE+β7 to select Treg cells that are regulatory, tissue-tropic, and emigrant, enabling targeted therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If anti-inflammatory medications are used to treat inflammatory bowel diseases, then inflammation is reduced, but adverse reactions occur and patients need to reduce dosage
Solution Approach 1:
The patent uses regulatory T-cells as biological mediators to restore immune balance. These cells act as intermediaries between the immune system and inflamed tissue, suppressing pathological inflammation through physiological mechanisms rather than pharmacological suppression, thereby avoiding drug-induced adverse reactions
Solution Approach 2:
The therapy employs the patient's own regulatory T-cells (autologous cells) to treat the disease. The cells are harvested, expanded, and reinfused to restore the patient's own immune regulation capacity, eliminating the need for external pharmaceutical agents and their associated side effects
2Adaptability or versatility
If Treg cells are used for cellular immunotherapy, then targeted treatment is achieved, but it remains difficult to identify suitable Treg cells due to lack of consistent correlation between Treg function and abundance
Solution Approach 1:
The patent identifies Treg cells with specific local qualities - particular homing receptor expression patterns (CCR9, α4β7, α4+αE+β7) that enable them to migrate to and localize in the gastrointestinal tract. This selective identification based on tissue-specific markers allows precise targeting of Treg cells to the site of inflammation
Solution Approach 2:
The patent uses cell surface markers as identifiable characteristics to distinguish therapeutic Treg cells from other T-cell populations. These molecular markers serve as recognizable signatures that enable detection, isolation, and selection of cells with the desired migratory and therapeutic properties
3Ease of operation
If Treg cells migrate to intestinal mucosa, then local immune control is achieved, but migration efficiency varies affecting therapeutic outcomes
Solution Approach 1:
The patent selects Treg cells based on specific parameter profiles - expression levels of homing receptors (CCR9 for small bowel, α4β7 for mucosal tissue, α4+αE+β7 for retention). By controlling these molecular parameters during cell selection and expansion, the therapy ensures reliable migratory behavior and localization efficiency
Data Source
AI summary
The present invention relates to a composition comprising an isolated CD4+ Treg cell population, wherein the Treg cells have signatures for i) identifying that the T-cells are CD4+ regulatory Tcells, ii) identifying that the Treg cells are tissue type tropic, i.e they can migrate to the diseased tissue, iii) optionally identifying that the Treg cells are tropic with respect to the diseased tissue, i.e. they are homing cells, iv) identifying that the Treg cells are emigrant cells, i.e. they originate from the target tissue, and v) optionally identifying that the Treg cells are retained in the target tissue and optionally one or more X-signatures and/or one or more Y-signatures and one ore more Z-signatures.